Paolo G Casali
@casali_pg
Followers
2K
Following
3
Statuses
276
Medical oncologist, treating sarcoma patients and teaching oncology, advocating rare cancers, hoping for new methods of clinical decision-making and research
Milan, Italy, EU
Joined January 2012
@OliverVarhelyi Thank you, indeed, for trusting the European oncology community of our Joint Action, due to create Networks of Expertise of the EU on: hi-tech medicine; omics; poor-prognosis cancers; palliative care; survivorship; cancer in adolescents and young adults; personalised prevention
0
0
0
RT @OliverVarhelyi: Today marks the launch of one of the biggest ever Joint Actions on cancer - backed by €40.5 million under #EU4Health.…
0
10
0
EU Joint Action on Networks of Expertise (JANE 1) just closed, knocking on the EU Parliament’s doors asking to politically address the many challenges of cancer healthcare networking. JANE 2 ready to start and give birth to seven new Networks of Expertise on cancer in the EU…
0
9
24
Implementing precision medicine implies a paradigm change in research methodology; implementing personalized medicine implies a paradigm change in methodology of clinical decision-making. Explainable AI is part of the solutions, but these should be made explicit.
Important considerations on global implementation of #precisionmedicine by @VivekSubbiah
#ESMO2024 @myESMO
@isliquidbiopsy
0
0
4
@bvantine1 @CCR_AACR Agree and would add that, generally, OR is questioned as a surrogate for OS or QoL. Though uncontrolled, here a benefit in QoL is directly suggested. So, do we need OR? And should we use a ‘phase 2’ methodology for an efficacy (not just activity) study, only because uncontrolled?
0
1
2
All saddened by losing his strong interpretation of a medical specialty in transformation, his total commitment to a disease, his humor in multidisciplinarity…
A giant among us has departed. Prof. Chris D.M.Fletcher passed away peacefully yesterday in Boston. He impacted our entire field, and he will be missed greatly. It was an honor to work with him and to learn from him.
0
0
7
RT @ItaSarcomaGroup: 🎗️July is Sarcoma Awareness Month!! The mission of #ISG is to improve the quality of care for patients battling #sarc…
0
16
0
RT @ERN_EURACAN: 📢Registrations still open for the next G1 virtual grand round. Send an email to johanna.schell@lyon.unicancer.fr to receiv…
0
3
0
RT @ERN_EURACAN: 📢Registrations open for the third EURACAN grand round to learn more about the results of the IMADGIST study presented by P…
0
1
0
@herbloong @jeanyvesblay @myESMO @AACR Thanks, indeed. The third EURACAN G1 virtual ‘grand round’, with A LeCesne, already planned on June 7th, 1:00PM CEST, to discuss if/how this may change our state of the art…
0
0
2
@JAMAOnc Are you sure that OS, as assessed without considering all its confounding factors, and quality of life, as assessed with current methodologies, do reflect an actual clinical benefit? Why not focusing on the magnitude of so called ‘surrogates’, which probably is the real issue?!
1
0
2
RT @ERN_EURACAN: Join the first @ERN_EURACAN virtual grand round, with Dr Patricia Pautier from @GustaveRoussy 🗓️Friday 5 April 1:00 CET >…
0
2
0
Thanks the new Spanish EU Presidency for hosting the EU Joint Action on Networks of Expertise. Cancer care networking can be such an added value of Europe that its many challenges must be addressed assertively, first working on the interplay between the EU and the national level!
0
3
30
My take: our common advocacy about healthcare networking in the EU should focus on viewing it as networking of national/regional networking and allowing the role of full partners to scientific/professional societies as well as patient advocacy groups.
0
2
9
RT @EU_Health: We cannot overstate the importance of accurate diagnosis & effective treatment in the fight against cancer. This is why the…
0
6
0
Thanks #ESMOSarcomaandrarecancers23 for allocating a session to EU networking. The Joint Actions CRANE and JANE are there to collect the needs and requests of the European oncology community to optimize future Network of Comprehensive Cancer Centers and Networks of Expertise!
1
5
26
My point: development of drugs in oncology can be agnostic, but then their clinical positioning should be investigated within the specific cancer (however defined)…
Very interesting talks and insightful discussion on histology-independent treatments in #rarecancers #precisiononcology #ESMOSarcomaAndRareCancers23
1
4
20
RT @ERN_EURACAN: Today is #RareDiseaseDay! It is the globally-coordinated movement on rare diseases, including rare cancers, which aims fo…
0
56
0
RT @eurordis: Today is #WorldCancerDay. 1 in 5 cancers is a rare cancer. There are an estimated 5.1 million people living with rare cancer…
0
10
0
RT @ACCMEDorg: Corso Residenziale 🔸Decidere in oncologia. Uso dell’analisi decisionale in: melanoma, sarcomi e GIST, tumori della testa e c…
0
1
0